Novel and Innovative Strategies to Treat Ventilator-Associated Pneumonia: Optimizing the Duration of Therapy and Nebulizing Antimicrobial Agents

ABSTRACT

Ventilator-associated pneumonia (VAP) is responsible for approximately half of the infections acquired in the intensive care unit (ICU) and represents one of the principal reasons for prescribing antibiotics in this setting. Because unnecessary prolongation of antimicrobial therapy and insufficient dosing of antibiotics at the site of infection in patients with true bacterial infection may lead to the selection of multidrug-resistant microorganisms without improving clinical outcome, efforts to reduce the duration of therapy and optimize pulmonary penetration of antimicrobial agents are warranted. An 8-day regimen can probably be standard for patients with VAP. Possible exceptions to this recommendation include immunosuppressed patients, those whose initial antimicrobial treatment was not appropriate for the causative microorganism(s), and patients whose infection was caused by very difficult-to-treat microorganisms and had no improvement in clinical signs of infection. Nebulizing concentration-dependent antibiotics such as aminoglycosides during mechanical ventilation can markedly increase tissue penetration in foci of pneumonia as compared with intravenous administration. The superiority in terms of pulmonary penetration and antibacterial efficacy of this route of administration was demonstrated in a model of ventilated piglets with and without bronchopneumonia.

Ventilator-associated pneumonia - quantitative cultures - antimicrobial treatment - duration of therapy - multidrug-resistant microorganisms - aerosols - piglets - amikacin

REFERENCES

• 1 Bergmans D C, Bonten M J, Gaillard C A et al.. Indications for antibiotic use in ICU patients: a one-year prospective surveillance.  J Antimicrob Chemother. 1997;  39 527-535
• 2 American Thoracic Society/Infections Diseases Society of America . Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.  Am J Respir Crit Care Med. 2005;  171 388-416
• 3 Chastre J, Fagon J Y. Ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2002;  165 867-903
• 4 American Thoracic Society . Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: a consensus statement, American Thoracic Society, November 1995.  Am J Respir Crit Care Med. 1996;  153 1711-1725
• 5 Fink M P, Snydman D R, Niederman M S et al.. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.  Antimicrob Agents Chemother. 1994;  38 547-557
• 6 Dennesen P J, van der Ven A J, Kessels A G, Ramsay G, Bonten M J. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2001;  163 1371-1375
• 7 Combes A, Figliolini C, Trouillet J L et al.. Factors predicting ventilator-associated pneumonia recurrence.  Crit Care Med. 2003;  31 1102-1107
• 8 Luna C M, Blanzaco D, Niederman M S et al.. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome.  Crit Care Med. 2003;  31 676-682
• 9 Singh N, Rogers P, Atwood C W, Wagener M M, Yu V L. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription.  Am J Respir Crit Care Med. 2000;  162 505-511
• 10 Chastre J, Wolff M, Fagon J Y et al.. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.  JAMA. 2003;  290 2588-2598
• 11 Ibrahim E H, Ward S, Sherman G, Schaiff R, Fraser V J, Kollef M H. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia.  Crit Care Med. 2001;  29 1109-1115
• 12 Micek S T, Ward S, Fraser V J, Kollef M H. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia.  Chest. 2004;  125 1791-1799
• 13 Froon A H, Bonten M J, Gaillard C A et al.. Prediction of clinical severity and outcome of ventilator-associated pneumonia: comparison of simplified acute physiology score with systemic inflammatory mediators.  Am J Respir Crit Care Med. 1998;  158 1026-1031
• 14 Duflo F, Debon R, Goudable J, Chassard D, Allaouchiche B. Alveolar and serum oxidative stress in ventilator-associated pneumonia.  Br J Anaesth. 2002;  89 231-236
• 15 Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection.  Lancet. 1993;  341 515-518
• 16 Harbarth S, Holeckova K, Froidevaux C et al.. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.  Am J Respir Crit Care Med. 2001;  164 396-402
• 17 Oberhoffer M, Stonans I, Russwurm S et al.. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro.  J Lab Clin Med. 1999;  134 49-55
• 18 Duflo F, Debon R, Monneret G, Bienvenu J, Chassard D, Allaouchiche B. Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia.  Anesthesiology. 2002;  96 74-79
• 19 Luyt C E, Guerin V, Combes A et al.. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2005;  171 48-53
• 20 Dhand R. Maximizing aerosol delivery during mechanical ventilation: go with the flow and go slow.  Intensive Care Med. 2003;  29 1041-1042
• 21 Dhand R. Basic techniques for aerosol delivery during mechanical ventilation.  Respir Care. 2004;  49 611-622
• 22 Hess D, Fisher D, Williams P, Pooler S, Kacmarek R M. Medication nebulizer performance: effects of diluent volume, nebulizer flow, and nebulizer brand.  Chest. 1996;  110 498-505
• 23 Duarte A G, Fink J B, Dhand R. Inhalation therapy during mechanical ventilation.  Respir Care Clin N Am. 2001;  7 233-260
• 24 Le Conte P, Potel G, Peltier P et al.. Lung distribution and pharmacokinetics of aerosolized tobramycin.  Am Rev Respir Dis. 1993;  147 1279-1282
• 25 O’Doherty M J, Thomas S H, Page C J, Treacher D F, Nunan T O. Delivery of a nebulized aerosol to a lung model during mechanical ventilation: effect of ventilator settings and nebulizer type, position, and volume of fill.  Am Rev Respir Dis. 1992;  146 383-388
• 26 Harvey C J, O’Doherty M J, Page C J, Thomas S H, Nunan T O, Treacher D F. Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation.  Eur Respir J. 1997;  10 905-909
• 27 O’Riordan T G, Palmer L B, Smaldone G C. Aerosol deposition in mechanically ventilated patients: optimizing nebulizer delivery.  Am J Respir Crit Care Med. 1994;  149 214-219
• 28 Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol.  Respir Care. 2002;  47 1406-1416 , discussion 1416-1418
• 29 Miller D D, Amin M M, Palmer L B, Shah A R, Smaldone G C. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation.  Am J Respir Crit Care Med. 2003;  168 1205-1209 , Epub 2003 Jul 31
• 30 O’Riordan T G, Greco M J, Perry R J, Smaldone G C. Nebulizer function during mechanical ventilation.  Am Rev Respir Dis. 1992;  145 1117-1122
• 31 Ferron G A, Kerrebijn K F, Weber J. Properties of aerosols produced with three nebulizers.  Am Rev Respir Dis. 1976;  114 899-908
• 32 Fuller H D, Dolovich M B, Posmituck G, Pack W W, Newhouse M T. Pressurized aerosol versus jet aerosol delivery to mechanically ventilated patients: comparison of dose to the lungs.  Am Rev Respir Dis. 1990;  141 440-444
• 33 Habib D M, Garner S S, Brandeburg S. Effect of helium-oxygen on delivery of albuterol in a pediatric, volume-cycled, ventilated lung model.  Pharmacotherapy. 1999;  19 143-149
• 34 Goode M L, Fink J B, Dhand R, Tobin M J. Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation.  Am J Respir Crit Care Med. 2001;  163 109-114
• 35 Tonnellier M, Ferrari F, Goldstein I, Sartorius A, Marquette C H, Rouby J J. Intravenous versus nebulized ceftazidime in ventilated piglets with and without experimental bronchopneumonia: comparative effects of helium and nitrogen.  Anesthesiology. 2005;  102 995-1000
• 36 Thomas S H, O’Doherty M J, Page C J, Treacher D F, Nunan T O. Delivery of ultrasonic nebulized aerosols to a lung model during mechanical ventilation.  Am Rev Respir Dis. 1993;  148 872-877
• 37 Goldstein I, Wallet F, Robert J, Becquemin M H, Marquette C H, Rouby J J. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs.  Am J Respir Crit Care Med. 2002;  165 171-175
• 38 Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette C H, Rouby J J. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets.  Am J Respir Crit Care Med. 2002;  166 1375-1381
• 39 Goldstein I, Bughalo M T, Marquette C H, Lenaour G, Lu Q, Rouby J J. Mechanical ventilation-induced air-space enlargement during experimental pneumonia in piglets.  Am J Respir Crit Care Med. 2001;  163 958-964
• 40 Ferrari F, Goldstein I, Nieszkowska A, Elman M, Marquette C H, Rouby J J. Lack of lung tissue and systemic accumulation after consecutive daily aerosols of amikacin in ventilated piglets with healthy lungs.  Anesthesiology. 2003;  98 1016-1019
• 41 Elman M, Goldstein I, Marquette C H, Wallet F, Lenaour G, Rouby J J. Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia.  Anesthesiology. 2002;  97 199-206
• 42 Matthay M A. Function of the alveolar epithelial barrier under pathologic conditions.  Chest. 1994;  105 67S-74S
• 43 Berendt R F, Long G G, Walker J S. Treatment of respiratory Klebsiella pneumoniae infection in mice with aerosols of kanamycin.  Antimicrob Agents Chemother. 1975;  8 585-590
• 44 Makhoul I R, Merzbach D, Lichtig C, Berant M. Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: comparison of aerosol and systemic administration.  J Infect Dis. 1993;  168 1296-1299
• 45 Greenfield S, Teres D, Bushnell L S, Hedley-Whyte J, Feingold D S. Prevention of gram-negative bacillary pneumonia using aerosol polymyxin as prophylaxis, I: Effect on the colonization pattern of the upper respiratory tract of seriously ill patients.  J Clin Invest. 1973;  52 2935-2940
• 46 Klick J M, du Moulin G C, Hedley-Whyte J, Teres D, Bushnell L S, Feingold D S. Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis, II: Effect on the incidence of pneumonia in seriously ill patients.  J Clin Invest. 1975;  55 514-519
• 47 Rouby J J, Poete P, Martin de Lassale E et al.. Prevention of gram-negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients: histologic and bacteriologic study.  Intensive Care Med. 1994;  20 187-192
• 48 Feeley T W, Du Moulin G C, Hedley-Whyte J, Bushnell L S, Gilbert J P, Feingold D S. Aerosol polymyxin and pneumonia in seriously ill patients.  N Engl J Med. 1975;  293 471-475